分子向药物的治疗疗效对于PSA患者的肠炎:一个网络元分析
Daisuke Nakatsubo1, Takayoshi Morita1,2, Atsushi Kumanogoh1,3,4
1Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Rheumatology advances in practice
|July 18, 2025
概括
与其他分子向药物相比,upadacitinib和certolizumab在治疗牛皮关节炎 (PsA) 中的肠炎方面表现出更高的疗效. 这一发现凸显了对患有肠炎的PsA患者个性化治疗策略的需要.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肠炎是牛皮关节炎 (PsA) 发展的关键因素.
- 评估分子向治疗PSA肠炎的疗法的有效性对于患者管理至关重要.
研究的目的:
- 进行一个网络元分析,评估分子向治疗对PSA患者肠炎的疗法的疗效.
- 为了比较各种药物类别和单个药物的有效性,以解决肠炎和减少相关症状.
主要方法:
- 在PubMed,Web of Science,Scopus和ClinicalTrials.gov进行了系统的搜索,搜索到2025年4月的随机对照试验 (RCT).
- 包括RCT,重点是针对PsA患者肠炎的分子向疗法.
- 主要结局包括12周和24周内肠炎解决率和利兹肠炎指数得分减少,使用随机效应模型进行分析.
主要成果:
- 分析了28项涉及10,383名患有肠炎的PsA患者的RCT.
- 在24周后,与阿达利木马布相比,阿巴达西提尼比显著改善了肠炎的分辨率和利兹肠炎指数得分的减少.
- 塞尔科利祖马布还显示了利兹肠炎指数得分的显著降低,而其他Janus激酶抑制剂没有显示可比的有效性.
结论:
- 与其他分子向药物相比,upadacitinib和certolizumab在PsA患者的肠炎中表现出更大的治疗疗效.
- 不同的分子向疗法之间,即使在同一个药物类别内,治疗疗效也存在显著差异.
- 这些发现强调了开发量身定制的治疗策略的必要性,以管理PsA中的肠炎.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
226
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
226
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
236
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
236
01:22Dose-Response Relationship: Potency and Efficacy
5.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.2K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
257
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
257
01:26Targets for Drug Action: Overview
7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K